{"id":"oral-administration-of-ipragliflozin","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"2-5","effect":"Polyuria"},{"rate":"1-3","effect":"Polydipsia"},{"rate":null,"effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2018096","moleculeType":"Small molecule","molecularWeight":"404.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an SGLT2 inhibitor, ipragliflozin blocks the SGLT2 transporter on the proximal tubule of the nephron, preventing the reabsorption of filtered glucose. This leads to increased urinary glucose excretion (glucosuria) and a reduction in blood glucose levels independent of insulin secretion. The mechanism also provides cardiovascular and renal protective benefits beyond glycemic control.","oneSentence":"Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:52.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT01316107","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":122},{"nctId":"NCT01117584","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-04-06","conditions":"Type 2 Diabetes Mellitus","enrollment":343},{"nctId":"NCT02847091","phase":"PHASE4","title":"Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-07-29","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT02897219","phase":"PHASE3","title":"A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-08-29","conditions":"Type 1 Diabetes Mellitus","enrollment":175},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT01514838","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2012-04-23","conditions":"Type II Diabetes Mellitus","enrollment":46},{"nctId":"NCT02291874","phase":"PHASE4","title":"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT02791035","phase":"PHASE4","title":"Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-06","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT02297620","phase":"","title":"The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04","conditions":"Type 2 Diabetes","enrollment":8687},{"nctId":"NCT01232413","phase":"PHASE1","title":"A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09","conditions":"Healthy Subjects, Cardiac Repolarization","enrollment":88},{"nctId":"NCT01121198","phase":"PHASE1","title":"A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":"Healthy Volunteer, Pharmacokinetics of ASP1941","enrollment":84},{"nctId":"NCT01104532","phase":"PHASE1","title":"A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":"Healthy, Pharmacokinetics of ASP1941","enrollment":64},{"nctId":"NCT01088919","phase":"PHASE1","title":"A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-11","conditions":"Healthy, Pharmacokinetics of ASP1941","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral administration of Ipragliflozin","genericName":"Oral administration of Ipragliflozin","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}